Home/BioArctic AB/Mikael Lindstam
ML

Mikael Lindstam

Chief Business Development Officer

BioArctic AB

BioArctic AB Pipeline

DrugIndicationPhase
Lecanemab (Leqembi®)Early Alzheimer's DiseaseApproved
BAN2802Alzheimer's DiseasePreclinical
Lecanemab SCAlzheimer's DiseasePhase 3
ABBV-0805Parkinson's DiseasePhase 1
BAN1202Parkinson's DiseasePreclinical